Featured Research

from universities, journals, and other organizations

Key molecule that blocks abnormal blood vessel growth in tumors identified

Date:
September 21, 2011
Source:
H. Lee Moffitt Cancer Center & Research Institute
Summary:
A new and better understanding of blood vessel growth and vascular development (angiogenesis) in cancer has been made possible by new research.

A new and better understanding of blood vessel growth and vascular development (angiogenesis) in cancer has been made possible by research carried out by a team of scientists from Moffitt Cancer Center, the University of Florida, Harvard University, Yale University and the Children's Hospital of Los Angeles.

The research team published the results of their investigation in a recent issue of Proceedings of the National Academy of Sciences.

"Vascular development is a fundamental biological process that is tightly controlled by both pro-and anti-angiogenic mechanisms," said Edward Seto, Ph.D., a co-author of the study and professor and chairman of the Department of Molecular Oncology at Moffitt. "Physiological angiogenesis occurs in adults only under specific settings. Excess angiogenesis contributes to a variety of diseases, including cancer. In cancer, vascular endothelial growth factor (VEGF) is commonly overproduced."

The goal of the research was to determine how angiogenesis is regulated by positive and negative biological activities.

"Understanding the biological principles that direct vascular growth has important clinical implications because cancers are highly vascularized," concluded Seto.

This meant seeking a better understanding of the relationship between the chromatin insulator binding factor CTCF and how it regulates VEGF expression.

"At the heart of vascular development is VEGF which, in precise doses, is an important stimulator of normal blood vessel growth," explained Seto. "However, VEGF -- probably the most important stimulator of normal and pathological blood vessel growth -- is regulated by a number of factors."

According to Seto, the study suggests that CTCF can block VEGF from being activated. Therefore, targeting CTCF may be an effective way to fine tune VEGF and control angiogenesis. The potential to manipulate CTCF opens a window to regulate VEGF and subsequently, the potential to manage angiogenesis and cancer.

"The real significance of this work has been apparent in experiments done at the University of Florida and at Harvard University, where our colleagues used mouse models to demonstrate that depletion of CTCF produces excess angiogenesis in animals," explained Seto. "Like finding a small key piece in a giant puzzle, it's truly exciting."


Story Source:

The above story is based on materials provided by H. Lee Moffitt Cancer Center & Research Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. M. Tang, B. Chen, T. Lin, Z. Li, C. Pardo, C. Pampo, J. Chen, C.-L. Lien, L. Wu, L. Ai, H. Wang, K. Yao, S. P. Oh, E. Seto, L. E. H. Smith, D. W. Siemann, M. P. Kladde, C. L. Cepko, J. Lu. Restraint of angiogenesis by zinc finger transcription factor CTCF-dependent chromatin insulation. Proceedings of the National Academy of Sciences, 2011; 108 (37): 15231 DOI: 10.1073/pnas.1104662108

Cite This Page:

H. Lee Moffitt Cancer Center & Research Institute. "Key molecule that blocks abnormal blood vessel growth in tumors identified." ScienceDaily. ScienceDaily, 21 September 2011. <www.sciencedaily.com/releases/2011/09/110921133206.htm>.
H. Lee Moffitt Cancer Center & Research Institute. (2011, September 21). Key molecule that blocks abnormal blood vessel growth in tumors identified. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2011/09/110921133206.htm
H. Lee Moffitt Cancer Center & Research Institute. "Key molecule that blocks abnormal blood vessel growth in tumors identified." ScienceDaily. www.sciencedaily.com/releases/2011/09/110921133206.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
China's Ageing Millions Look Forward to Bleak Future

China's Ageing Millions Look Forward to Bleak Future

AFP (July 24, 2014) China's elderly population is expanding so quickly that children struggle to look after them, pushing them to do something unexpected in Chinese society- move their parents into a nursing home. Duration: 02:07 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins